CN112691185A - Anti-tumor formula and extraction method thereof - Google Patents
Anti-tumor formula and extraction method thereof Download PDFInfo
- Publication number
- CN112691185A CN112691185A CN202011612272.9A CN202011612272A CN112691185A CN 112691185 A CN112691185 A CN 112691185A CN 202011612272 A CN202011612272 A CN 202011612272A CN 112691185 A CN112691185 A CN 112691185A
- Authority
- CN
- China
- Prior art keywords
- tumor
- parts
- extract
- lipid
- enzyme
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 47
- 238000009472 formulation Methods 0.000 title claims description 12
- 238000000605 extraction Methods 0.000 title claims description 8
- 229930182558 Sterol Natural products 0.000 claims abstract description 24
- 150000002632 lipids Chemical class 0.000 claims abstract description 24
- 150000003432 sterols Chemical class 0.000 claims abstract description 24
- 235000003702 sterols Nutrition 0.000 claims abstract description 24
- 150000004676 glycans Chemical class 0.000 claims abstract description 19
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 19
- 239000005017 polysaccharide Substances 0.000 claims abstract description 19
- 102000004856 Lectins Human genes 0.000 claims abstract description 18
- 108090001090 Lectins Proteins 0.000 claims abstract description 18
- 239000002523 lectin Substances 0.000 claims abstract description 18
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 18
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 18
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 18
- 239000002994 raw material Substances 0.000 claims abstract description 18
- 229940089161 ginsenoside Drugs 0.000 claims abstract description 14
- 229930182494 ginsenoside Natural products 0.000 claims abstract description 14
- 238000011282 treatment Methods 0.000 claims abstract description 10
- 102000004190 Enzymes Human genes 0.000 claims description 24
- 108090000790 Enzymes Proteins 0.000 claims description 24
- 229940088598 enzyme Drugs 0.000 claims description 24
- 241001327634 Agaricus blazei Species 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 19
- 239000000284 extract Substances 0.000 claims description 18
- 239000000047 product Substances 0.000 claims description 16
- 238000003756 stirring Methods 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 238000001914 filtration Methods 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 13
- 239000006228 supernatant Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 238000005303 weighing Methods 0.000 claims description 8
- 241000208340 Araliaceae Species 0.000 claims description 7
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 7
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 7
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 7
- 235000008434 ginseng Nutrition 0.000 claims description 7
- 239000004382 Amylase Substances 0.000 claims description 6
- 102000013142 Amylases Human genes 0.000 claims description 6
- 108010065511 Amylases Proteins 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- 235000019418 amylase Nutrition 0.000 claims description 6
- 230000007935 neutral effect Effects 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 238000001556 precipitation Methods 0.000 claims description 6
- 238000010298 pulverizing process Methods 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 239000012153 distilled water Substances 0.000 claims description 5
- 239000002244 precipitate Substances 0.000 claims description 5
- 238000002791 soaking Methods 0.000 claims description 5
- 108090000145 Bacillolysin Proteins 0.000 claims description 4
- 102000035092 Neutral proteases Human genes 0.000 claims description 4
- 108091005507 Neutral proteases Proteins 0.000 claims description 4
- 108090000526 Papain Proteins 0.000 claims description 4
- 239000004365 Protease Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 229940055729 papain Drugs 0.000 claims description 4
- 235000019834 papain Nutrition 0.000 claims description 4
- 108010059892 Cellulase Proteins 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 3
- 210000002421 cell wall Anatomy 0.000 claims description 3
- 229940106157 cellulase Drugs 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 235000020710 ginseng extract Nutrition 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 230000000415 inactivating effect Effects 0.000 claims description 3
- 239000012044 organic layer Substances 0.000 claims description 3
- 230000001376 precipitating effect Effects 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000007071 enzymatic hydrolysis Effects 0.000 claims description 2
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000000118 anti-neoplastic effect Effects 0.000 claims 1
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 30
- 239000003814 drug Substances 0.000 abstract description 23
- 230000000694 effects Effects 0.000 abstract description 18
- 241000721047 Danaus plexippus Species 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 241000382455 Angelica sinensis Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 241000037740 Coptis chinensis Species 0.000 description 1
- 235000014375 Curcuma Nutrition 0.000 description 1
- 244000164480 Curcuma aromatica Species 0.000 description 1
- 240000009138 Curcuma zedoaria Species 0.000 description 1
- 235000003405 Curcuma zedoaria Nutrition 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 244000179560 Prunella vulgaris Species 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 description 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000000459 effect on growth Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000021090 palsy Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000008113 selfheal Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 231100000456 subacute toxicity Toxicity 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000009602 toxicology test Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 235000019509 white turmeric Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an anti-tumor formula which comprises the following raw materials in parts by weight: 10-20 parts of nucleic acid, 10-20 parts of lectin, 10-20 parts of polysaccharide, 10-20 parts of ginsenoside, 5-10 parts of lipid and 5-10 parts of sterol. The anti-tumor formula provided by the invention conforms to the principle of 'monarch, minister, assistant and guide' specified by the formula of a traditional Chinese medicine prescription, is rigorous in formula and proper in compatibility, conforms to the treatment principles of 'nut-on-the-go', 'knot-on-the-go', 'leaving-on-the-go' and 'deficiency-on-the-go' in traditional Chinese medicine treatment of tumors, and can achieve the effect of effectively treating the tumors by adopting the raw materials in the invention.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to an anti-tumor formula and an extraction method thereof.
Background
With the increasing severe environmental pollution, the incidence of tumors is higher and higher, which seriously affects the life and lives of human beings. For the treatment of tumor, modern medicine mostly adopts surgery, radiotherapy, chemotherapy, radio frequency and intervention and other methods. Some domestic manufacturers also have part of anti-tumor drugs, but most of the anti-tumor drugs are fungus wall-broken powder or simpler components.
Modern medicine mainly treats tumors by chemotherapy, radiotherapy and operation, but a large number of clinical treatments prove that the chemotherapy and the radiotherapy are accompanied by toxic and side effects with different degrees, the tumors are killed, normal cells of a human body are killed to a great extent, and vomiting, fatigue, diarrhea, leukopenia, tissue edema, nerve palsy, tissue necrosis and the like are brought to the human body.
In recent years, the traditional Chinese medicine treatment of tumors is called as a unique therapy, the traditional Chinese medicine considers that blood stasis blockage, phlegm-dampness coagulation, heat-toxin accumulation and deficiency of vital qi are pathogenesis of tumors, and according to the pathogenesis and occurrence and development rule of the tumors, the traditional Chinese medicine anticancer treatment mainly has four basic rules of strengthening body resistance and consolidating constitution, clearing heat and detoxicating, activating blood and dissolving stasis and softening hardness and dissipating stagnation. The mechanism of the traditional Chinese medicine for treating the tumor mainly has the functions of directly inhibiting and killing tumor cells, inhibiting tumor angiogenesis, inhibiting telomerase activity, inducing cell differentiation, regulating cell signal conduction, resisting microtubule, enhancing immunity, reversing multidrug resistance and the like. The traditional Chinese medicine has long history of treating tumors and unique curative effect, and a large number of clinical and experimental researches prove that the traditional Chinese medicine can relieve tumor symptoms, improve the life quality of patients and reduce the death rate.
However, the existing methods for treating tumors generally have the defects of slow effect, unobvious effect and the like, and currently, the methods still do not really deserve the experience and achievement of general popularization and use.
Therefore, the problem to be solved by those skilled in the art is how to provide an antitumor formulation with low cost, wide drug sources, good therapeutic effect and low toxicity.
Disclosure of Invention
In view of the above, the invention provides an anti-tumor formulation with low cost, wide drug sources, good curative effect and low toxicity and an extraction method thereof.
In order to achieve the purpose, the invention adopts the following technical scheme: an anti-tumor formula comprises the following raw materials in parts by weight: 10-20 parts of nucleic acid, 10-20 parts of lectin, 10-20 parts of polysaccharide, 10-20 parts of ginsenoside, 5-10 parts of lipid and 5-10 parts of sterol.
The invention has the following beneficial effects: the anti-tumor formula of the invention accords with the principle of 'monarch, minister, assistant and guide' which is unique in the formula of the traditional Chinese medicine prescription, has strict formula and proper compatibility, accords with the treatment principles of 'nut-on-the-go', 'knot-on-the-go', 'leaving-on-the-go' and 'deficiency-on-the-go' for treating tumors in the traditional Chinese medicine, and can achieve the effect of effectively treating the tumors by adopting the raw materials in the invention.
Preferably, the nucleic acids, lectins, polysaccharides, lipids and sterols are derived from an extract of agaricus blazei.
Preferably, the method for extracting the agaricus blazei murill extract comprises the following steps:
(1) pulverizing Agaricus blazei Murill dried to constant weight state, sieving with 80-150 mesh sieve, adding cell wall breaking enzyme, performing enzymolysis in ultrasonic generator at 22-24KHz frequency to obtain liquid, adding 18-25 mass times of distilled water, dissolving, stirring, and extracting with complex enzyme in 44-54 deg.C constant temperature water bath for 46-56 min; inactivating enzyme in boiling water for 5-7min, centrifuging at 3000r/min at 2500-;
(2) carrying out enzymolysis on the extracting solution, concentrating the extracting solution to 1/2-1/3 of the volume of the extracting solution, then adjusting the isoelectric point to pH 2 by adopting hydrochloric acid, filtering to obtain nucleic acid and supernatant, adjusting the pH of the supernatant to 8, and filtering to obtain lectin and supernatant;
(3) carrying out alcohol precipitation treatment on the clear liquid obtained in the step (2), and filtering to obtain polysaccharide;
(4) adding an organic solvent into the filter residue obtained in the step (1), centrifuging to obtain a supernatant, and removing the solvent to obtain lipid and sterols;
(5) adding organic solvent into lipid and sterol, stirring, standing for layering, washing to neutral to obtain neutral organic layer, separating with silica gel chromatographic column, eluting, collecting eluate, concentrating to remove solvent to obtain sterol, and precipitating to obtain lipid.
Preferably, in the step (1), the wall-breaking enzyme agent is prepared from cellulase and amylase according to a mass ratio of (1-2): (1-4); the mass ratio of the wall-breaking enzyme agent to the agaricus blazei murill is (0.5-2): 100, respectively;
in the step (1) and the step (2), the complex enzyme is neutral protease and papain in a mass ratio of (1-3): (2-5); the mass ratio of the compound enzyme to the agaricus blazei murill is (0.1-1): 100.
the organic solvent in the steps (4) and (5) is n-butanol or propanol, and the dosage of the organic solvent is 5-8 times of the filter residue or the precipitate
Adopt above-mentioned technical scheme's beneficial effect: by adopting the extraction method of the invention, each component in the agaricus blazei murill extract can be extracted continuously.
Preferably, the extraction method of the ginseng extract comprises the following steps:
pulverizing Ginseng radix into 80-100 mesh powder, and performing enzymolysis; then respectively adding 8-10 times of ethanol for soaking, heating to 40-50 deg.C, keeping the temperature for 2-3h, filtering to obtain extractive solution, concentrating the obtained extract, adding water, extracting with saturated n-butanol for 3-4 times, adding equal volume of acetone into the extractive solution for precipitation, and drying the precipitate to obtain the Ginseng radix extract.
Preferably, the specific operation of the enzymatic hydrolysis is as follows: adding 5-7 times of 0.5-1% amylase into the powder for enzymolysis for 12-24 hr.
Preferably, the mass concentration of the ethanol is 40-50%; the soaking time is 12-24 h.
Adopt above-mentioned technical scheme's beneficial effect: greatly increases the precipitation of effective components and improves the yield of each extract.
The effects of the raw materials in the invention are as follows:
the Agaricus blazei Murill has mild nature and sweet taste, and has effects of nourishing brain, diminishing inflammation, invigorating kidney, reducing blood sugar, improving diabetes, reducing cholesterol, enhancing energy, improving arteriosclerosis, and preventing and treating cardiovascular diseases.
Agaricus blazei Murill extract: 1. enhancing the immune function of human body: by enhancing the function of the mononuclear macrophage system, the human body autoimmune function is enhanced, and the effects of inhibiting cell division and regulating immune system reaction are achieved, so that the growth of interfering virus is hindered. 2. Can promote the hematopoietic function of human bone marrow: by improving the suppression of chemotherapy on the hematopoietic function of bone marrow, the peripheral hemoglobin concentration, the total number of platelets and white blood cells tend to normal values, and simultaneously, the traditional Chinese medicine composition has an inhibitory effect on tumor cells, and can be taken for a long time to achieve the effects of strengthening body resistance and health care. 3. Can promote the effect of chemotherapeutic drugs cyclophosphamide and 5-Fu. 4. Has inhibitory effect on cell proliferation interfering leukemia. Physiologically active polysaccharide, and is suitable for treating children leukemia. 5. Has protective effect on liver and kidney, and can be taken for a long time. Due to the above effects, Agaricus blazei Murill has attracted much attention in Japan as a health care product. Has the special health-care function of double conditioning of activating immunity and strengthening body resistance, so the health-care tea is widely applied to patients. 6. The Agaricus blazei Murill has anticancer biological function.
Ginsenoside has effects of preventing and resisting tumor.
The invention also provides a preparation method of the anti-tumor formula, which comprises the following steps:
(1) weighing the raw materials according to the weight part of the anti-tumor composition for later use;
(2) and (3) uniformly stirring and mixing the nucleic acid, the lectin, the polysaccharide, the ginsenoside, the lipid and the sterol to obtain the anti-tumor product.
Preferably, in the step (2), the stirring temperature is 40-50 ℃ and the stirring time is 30-40 min.
The invention also provides application of the anti-tumor composition, which is characterized in that the anti-tumor product and a pharmaceutically acceptable carrier are prepared into any one of common oral preparations, and the oral preparation is capsule, granule, oral liquid, pill or tablet.
According to the technical scheme, compared with the prior art, the anti-tumor composition and the preparation method and application thereof are disclosed, and the anti-tumor composition is prepared by compounding the extracts serving as raw materials, selects a proper proportion for sharing, is a nutrient substance with different molecular structures, has partially same drug effects and respective outstanding drug effects, and organically combines the components together according to the proper proportion, so that the anti-tumor composition can complement and promote each other in the aspect of curative effect, furthest exerts the respective effects for resisting tumors, and can reduce the corresponding cost.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
The method for preparing the agaricus blazei murill extract in the following examples comprises the following steps:
(1) pulverizing Agaricus blazei Murill dried to constant weight state, sieving with 1000 mesh sieve, adding cell wall breaking enzyme, performing enzymolysis in an ultrasonic generator at 22KHz frequency to obtain liquid, adding 18 mass times of distilled water, dissolving, stirring, and extracting with complex enzyme in 44 deg.C constant temperature water bath for 46 min; inactivating enzyme of the extractive solution in boiling water for 5min, centrifuging at 2500r/min for 5min, and filtering to obtain residue and extractive solution; wherein the cellulase and the amylase are mixed according to the mass ratio of 1: 1, the mass ratio of the wall-breaking enzyme agent to the agaricus blazei murill is 0.5: 100, respectively; the compound enzyme is neutral protease and papain in a mass ratio of 1: 2, the mass ratio of the complex enzyme to the agaricus blazei murill is 0.1: 100, respectively;
(2) performing enzymolysis on the extracting solution by using complex enzyme, concentrating the extracting solution to 1/2 of the volume of the extracting solution, then adjusting the isoelectric point to pH 2 by using hydrochloric acid, filtering to obtain nucleic acid and supernatant, adjusting the pH of the supernatant to 8, and filtering to obtain lectin and clear solution; the compound enzyme is neutral protease and papain in a mass ratio of 1: 2, the mass ratio of the complex enzyme to the agaricus blazei murill is 0.3: 100, respectively;
(3) adding 75% ethanol with 6 times volume of the clear liquid obtained in the step (2), carrying out centrifugal treatment for 5min at 4000r/min, and filtering to obtain polysaccharide;
(4) adding 5 times of acetone solution into the filter residue obtained in the step (1), centrifuging at 4000r/min for 5min, collecting supernatant, removing solvent to obtain lipid and sterol precipitate;
(5) adding n-butanol 8 times the mass of lipid and sterol, stirring, standing for layering, washing to neutral to obtain neutral organic layer, passing through silica gel chromatographic column, eluting, collecting eluate, concentrating to remove solvent to obtain sterol, and precipitating to obtain lipid.
The extraction method of the ginseng extract comprises the following steps:
pulverizing Ginseng radix into 80 mesh powder, adding 6 times of 0.5% amylase, and performing enzymolysis for 12 hr; then respectively adding 8 times of ethanol for soaking, heating to 45 deg.C, keeping the temperature for 2 hr, filtering to obtain extractive solution, concentrating the obtained extract, adding water, extracting with saturated n-butanol for 3 times, adding equal volume of acetone into the extractive solution for precipitation, and drying the precipitate at 70 deg.C for 20min to obtain Ginseng radix extract.
Example 1
The anti-tumor formula comprises the following raw materials in parts by weight: 10g of nucleic acid, 10g of lectin, 10g of polysaccharide, 10g of ginsenoside, 5g of lipid and 5g of sterol;
the preparation method of the anti-tumor formula comprises the following steps:
(1) weighing the raw materials for later use;
(2) stirring nucleic acid, lectin, polysaccharide, ginsenoside, lipid, and sterol at 40 deg.C for 35min to obtain antitumor product.
Example 2
The anti-tumor formula comprises the following raw materials in parts by weight: 20g of nucleic acid, 20g of lectin, 20g of polysaccharide, 20g of ginsenoside, 10g of lipid and 10g of sterol;
the preparation method of the anti-tumor formula comprises the following steps:
(1) weighing the raw materials for later use;
(2) stirring nucleic acid, lectin, polysaccharide, ginsenoside, lipid, and sterol at 40 deg.C for 35min to obtain antitumor product.
Example 3
The anti-tumor formula comprises the following raw materials in parts by weight: 15g of nucleic acid, 15g of lectin, 15g of polysaccharide, 15g of ginsenoside, 8g of lipid and 8g of sterol;
the preparation method of the anti-tumor formula comprises the following steps:
(1) weighing the raw materials for later use;
(2) stirring nucleic acid, lectin, polysaccharide, ginsenoside, lipid, and sterol at 40 deg.C for 35min to obtain antitumor product.
Example 4
The anti-tumor formula comprises the following raw materials in parts by weight: 12g of nucleic acid, 12g of lectin, 12g of polysaccharide, 16g of ginsenoside, 7g of lipid and 9g of sterol;
the preparation method of the anti-tumor formula comprises the following steps:
(1) weighing the raw materials for later use;
(2) stirring nucleic acid, lectin, polysaccharide, ginsenoside, lipid, and sterol at 40 deg.C for 35min to obtain antitumor product.
Comparative example 1
The anti-tumor medicine comprises 15g of selfheal, 15g of coptis chinensis, 8g of liquorice, 7g of cinnamon, 7g of fructus evodiae, 7g of dried ginger, 8g of rhizoma sparganii, 8g of curcuma zedoary, 15g of angelica sinensis and 15g of ginseng.
The preparation method comprises the following steps: the raw materials are stirred and mixed evenly to obtain the antitumor drug.
Aiming at the research on the efficacy of the composition of the invention in antitumor medicine
Effect on growth of S180 solid tumors
50 mice are taken and inoculated with S180 tumor fluid subcutaneously, the next day is divided into 5 groups randomly, each group comprises 10 mice, and the groups respectively comprise a blank control group, a positive control group (cyclophosphamide), a low-dose group of the product in the embodiment 1 of the invention, a medium-dose group of the product in the embodiment 1 of the invention and a high-dose group of the product in the embodiment 1 of the invention, and the weights of the groups are weighed. Diluting with distilled water, and administrating by gavage administration according to 0.2mL/10g weight, wherein each time is in turn, continuously for 10 days, weighing the weight the next day after medicine is stopped, killing animals, stripping subcutaneous tumor mass, weighing tumor weight, and calculating the tumor inhibition rate, wherein the data are shown in the following table 1:
tumor inhibition (%) × (1-mean tumor weight in treatment group/mean tumor weight in placebo group) ×%;
table 1: the data on the tumor-inhibiting effect of S180 subcutaneous tumor-bearing mice are as follows
| Dosage (g/mL) | Average tumor weight (g) | Tumor inhibition Rate (%) | |
| Blank control group | 1.89 | ||
| Positive control group | 0.20 | 0.96 | 49.2 |
| Low dose group | 0.15 | 0.58 | 69.3 |
| Middle dose group | 0.25 | 0.44 | 76.7 |
| High dose group | 0.50 | 0.32 | 83.1 |
From the above table 1, it can be seen that the product of the present invention can achieve effective tumor inhibition.
Toxicology test
In order to ensure the subacute toxicity condition of the traditional Chinese medicine composition, the experiment is carried out on rats, 80 SD rats are randomly divided into 5 groups, 20 rats in each group are respectively pulverized by using the anti-tumor products prepared in the embodiments 1-4 of the invention, the pulverized anti-tumor products are diluted by using distilled water, and the anti-tumor products are irrigated by 0.2-0.8mL/10g per day for 30 days for observation.
In the test period, the appetite, behavior and feces of each group of mice are normal, the development is good, no obvious poisoning symptom exists, and the hemogram and serum indexes of each group are in the normal range.
The clinical medicine is fed for 30 days according to the dosage 3 times of the clinical medicine, no obvious toxic or side effect is seen, and the clinical medicine dosage of the medicine is safe.
The embodiments in the present description are described in a progressive manner, each embodiment focuses on differences from other embodiments, and the same and similar parts among the embodiments are referred to each other. The device disclosed by the embodiment corresponds to the method disclosed by the embodiment, so that the description is simple, and the relevant points can be referred to the method part for description.
The previous description of the disclosed embodiments is provided to enable any person skilled in the art to make or use the present invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of the invention. Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.
Claims (10)
1. An anti-tumor formula is characterized by comprising the following raw materials in parts by weight: 10-20 parts of nucleic acid, 10-20 parts of lectin, 10-20 parts of polysaccharide, 10-20 parts of ginsenoside, 5-10 parts of lipid and 5-10 parts of sterol.
2. The anti-neoplastic formulation according to claim 1, wherein the nucleic acids, lectins, polysaccharides, lipids and sterols are derived from an extract of Agaricus blazei.
3. The anti-tumor formulation according to claim 2, wherein the extraction method of the agaricus blazei murill extract comprises the following steps:
(1) pulverizing Agaricus blazei Murill dried to constant weight state, sieving with 80-150 mesh sieve, adding cell wall breaking enzyme, performing enzymolysis in ultrasonic generator at 22-24KHz frequency to obtain liquid, adding 18-25 mass times of distilled water, dissolving, stirring, and extracting with complex enzyme in 44-54 deg.C constant temperature water bath for 46-56 min; inactivating enzyme in boiling water for 5-7min, centrifuging at 3000r/min at 2500-;
(2) performing enzymolysis on the extract by using complex enzyme, concentrating the extract to 1/2-1/3 of the volume of the extract, adjusting the isoelectric point to pH 2 by using hydrochloric acid, filtering to obtain nucleic acid and supernatant, adjusting the pH of the supernatant to 8, and filtering to obtain lectin and supernatant;
(3) carrying out alcohol precipitation treatment on the clear liquid obtained in the step (2), and filtering to obtain polysaccharide;
(4) adding an organic solvent into the filter residue obtained in the step (1), centrifuging to obtain a supernatant, and removing the solvent to obtain lipid and sterols;
(5) adding organic solvent into lipid and sterol, stirring, standing for layering, washing to neutral to obtain neutral organic layer, separating with silica gel chromatographic column, eluting, collecting eluate, concentrating to remove solvent to obtain sterol, and precipitating to obtain lipid.
4. The anti-tumor formulation according to claim 3, wherein in the step (1), the wall-breaking enzyme is prepared from cellulase and amylase according to the mass ratio of (1-2): (1-4); the mass ratio of the wall-breaking enzyme agent to the agaricus blazei murill is (0.5-2): 100, respectively;
in the step (1) and the step (2), the complex enzyme is neutral protease and papain in a mass ratio of (1-3): (2-5); the mass ratio of the compound enzyme to the agaricus blazei murill is (0.1-1): 100.
5. the anti-tumor formulation according to any one of claims 1 to 4, wherein the ginseng extract is extracted by a method comprising the steps of:
pulverizing Ginseng radix into 80-100 mesh powder, and performing enzymolysis; then respectively adding 8-10 times of ethanol for soaking, heating to 40-50 deg.C, keeping the temperature for 2-3h, filtering to obtain extractive solution, concentrating the obtained extract, adding water, extracting with saturated n-butanol for 3-4 times, adding equal volume of acetone into the extractive solution for precipitation, and drying the precipitate to obtain the Ginseng radix extract.
6. The anti-tumor formulation according to claim 5, wherein the enzymatic hydrolysis comprises the following specific steps: adding 5-7 times of 0.5-1% amylase into the powder for enzymolysis for 12-24 hr.
7. The anti-tumor formulation according to claim 5, wherein the ethanol is present in an amount of 40 to 50% by weight; the soaking time is 12-24 h.
8. The preparation method of the anti-tumor formula is characterized by comprising the following steps:
(1) weighing the raw materials according to the weight parts of the anti-tumor formula of any one of claims 1 to 7 for later use;
(2) and (3) uniformly stirring and mixing the nucleic acid, the lectin, the polysaccharide, the ginsenoside, the lipid and the sterol to obtain the anti-tumor product.
9. The method for preparing an anti-tumor formulation according to claim 8, wherein the stirring temperature in step (2) is 40-50 ℃ for 30-40 min.
10. An anti-tumor composition application, which is characterized in that the anti-tumor formulation of any one of claims 1 to 7 or the anti-tumor product prepared by the preparation method of claim 8 or 9 and a pharmaceutically acceptable carrier are prepared into any one of common oral preparations, and the oral preparations are capsules, granules, oral liquids, pills or tablets.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011612272.9A CN112691185A (en) | 2020-12-30 | 2020-12-30 | Anti-tumor formula and extraction method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011612272.9A CN112691185A (en) | 2020-12-30 | 2020-12-30 | Anti-tumor formula and extraction method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112691185A true CN112691185A (en) | 2021-04-23 |
Family
ID=75511509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011612272.9A Pending CN112691185A (en) | 2020-12-30 | 2020-12-30 | Anti-tumor formula and extraction method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112691185A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019010813A1 (en) * | 2017-07-13 | 2019-01-17 | 吴炳新 | Microbial fermentation composition and use thereof |
-
2020
- 2020-12-30 CN CN202011612272.9A patent/CN112691185A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019010813A1 (en) * | 2017-07-13 | 2019-01-17 | 吴炳新 | Microbial fermentation composition and use thereof |
Non-Patent Citations (3)
| Title |
|---|
| 周晓兰等: "姬松茸的研究概况", 《福建轻纺》 * |
| 王芳等: "《癌症病人饮食保健指导书》", 31 March 2016, 天津科学技术出版社 * |
| 葛红霞: "姬松茸及其多糖的研究进展", 《畜牧与饲料科学》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101450165B (en) | Anti-cancer traditional Chinese medicine compound ganoderma preparation and preparation method thereof | |
| CN100500196C (en) | Method for preparing paris polyphylla total saponin | |
| CN102091314A (en) | Composition of dried ginger and evodia rutaecarpa, preparation method thereof and application thereof in preparing attenuating synergistic medicament in radiotherapy and chemotherapy of cancer | |
| CN102370695B (en) | Qinglongyi active extract, its preparation method and its application | |
| CN101850032B (en) | Anti-tumor traditional Chinese medicine composition and preparation method and application thereof | |
| CN101856374A (en) | Anti-aging compound | |
| CN102688295A (en) | Chinese medicine composition for controlling metabolic diseases as well as preparation method and application thereof | |
| CN101396373B (en) | Cinobufacini extract and preparation method thereof | |
| CN109232756B (en) | Suaeda salsa polysaccharide extract and preparation method and application thereof | |
| CN101129974A (en) | Traditional Chinese medicine composition for treating hepatopathy and method of preparing the same | |
| CN101120977B (en) | Medicine for treating tumor | |
| CN112691185A (en) | Anti-tumor formula and extraction method thereof | |
| CN104069194B (en) | A kind of Chinese medicine composition with antitumaous effect and its production and use | |
| CN104922295A (en) | Blood-nourishing and blood-enriching traditional Chinese medicine composition | |
| CN102139072B (en) | Chinese medicinal preparation for treating gynecological inflammation | |
| AU2021100051A4 (en) | Antitumor formula and extraction method thereof | |
| CN102078600A (en) | Anti-cancer compound ganoderma composition, application thereof and pharmaceutical composition containing same | |
| CN113134025A (en) | Application of broccoli extract in preventing and treating leukopenia | |
| CN100471488C (en) | Chinese medicine composition for transquilizing, warming Yang, benefiting Qi and nourishing heart and its prepn | |
| CN101584828B (en) | Preparation for Chinese medicinal composition for clearing lung-heat | |
| CN114404433B (en) | Pinoresinol diglucoside composition for improving microcirculation and preparation method thereof | |
| CN102652786B (en) | Application of total extract composite of Luiwei Dijhuang decoction in preparing medicament for treating diabetic nephropathy | |
| CN102836315A (en) | Chinese medicinal composition for preventing and conditioning prognosis tumors and preparation method thereof | |
| CN102652785B (en) | Liuwei Dihuang decoction total extract composition and preparation method and application thereof to preparation of drugs for treating heart, brain and testis complications caused by stress response | |
| CN102423384A (en) | Traditional Chinese drug preparation for treating lung cancer, and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210423 |